Nivolumab and ipilimumab combination therapy for melanoma efficacy, safety and clinical integration in metastatic and adjuvant settings

Abstract

Melanoma remains one of the most aggressive cutaneous malignancies, accounting for a disproportionate share of skin cancer-related mortality despite relatively lower incidence. Over the past decade, immune checkpoint inhibitors (ICIs) have revolutionized melanoma management, with dual blockade of programmed death receptor-1 (PD-1) and cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) representing one of the most impactful therapeutic advances. This narrative review critically examines the clinical integration of nivolumab-ipilimumab (Nivo-Ipi) combination therapy across metastatic, neoadjuvant, and adjuvant melanoma settings, with emphasis on efficacy, safety, and emerging clinical challenges. Evidence from pivotal randomized trials, particularly the 10-year final outcomes of CheckMate 067, demonstrates that Nivo-Ipi confers substantial improvements in overall survival compared with ipilimumab monotherapy, and numerically superior outcomes compared with nivolumab monotherapy-though the trial was not powered to formally establish this latter comparison. Landmark analyses reveal durable survival plateaus extending beyond seven years in approximately 31% of combination-treated patients, redefining expectations for advanced melanoma. However, this enhanced efficacy is accompanied by significantly higher rates of immune-related adverse events (irAEs), necessitating careful patient selection and proactive toxicity management. Emerging data from the NADINA trial establish a compelling neoadjuvant role for the combination, while the adjuvant CheckMate 915 trial failed to demonstrate recurrence-free survival benefit over nivolumab monotherapy. Future progress will depend on biomarker-driven personalization, refined sequencing strategies, and integration of the combination within an increasingly competitive first-line landscape that now includes nivolumab plus relatlimab.